PharmacoEconomics https://doi.org/10.1007/s40273-018-0668-8 SYSTEMATIC REVIEW Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review 1,2 3 4 • • Carlos E. Rodriguez-Martinez Monica P. Sossa-Bricen ˜ o Jose A. Castro-Rodriguez Springer International Publishing AG, part of Springer Nature 2018 Abstract Results A total of 72 studies were included in the review, Objective The objective of this article was to summarize classiﬁed as follows: medications for acute asthma treat- the ﬁndings of all the available studies on alternative ment (n = 5, 6.9%); inhaled corticosteroids (ICS) admin- pharmacological treatments for asthma and assess their istered alone or in conjunction with long-acting b-agonists methodological quality, as well as to identify the main (LABA) or tiotropium for chronic asthma treatment drivers of the cost effectiveness of pharmacological treat- (n = 38, 52.8%); direct comparisons between different ments for the disease. combinations of ICS, ICS/LABA, leukotriene receptor Methods A systematic review of the literature in seven antagonists (LTRA), and sodium cromoglycate for chronic electronic databases was conducted in order to identify all asthma treatment (n = 14, 19.4%); and omalizumab for the available health economic evidence on alternative chronic asthma treatment (n = 15, 20.8%). ICS were pharmacological treatments for asthma published up
PharmacoEconomics – Springer Journals
Published: Jun 4, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera